

The Ramaciotti Foundations

2025 Health Investment Grants

Ramaciotti Health Investment Grants of up to \$100,000 are awarded to individuals for a contribution towards the undertaking of health or medical research with the potential path to clinical application within five years. They are intended to provide enabling research support for autonomous early career investigators who are taking or have recently taken, a substantial position. Grants are awarded by Perpetual, as trustee of the Ramaciotti Foundations, on the recommendation of the Ramaciotti Scientific Advisory Committee.

Perpetual is pleased to congratulate this year's recipients.

RECIPIENT	INSTITUTION	PROJECT
Dr Jessica Chitty <i>Derek Hart Memorial Award Recipient</i>	Garvan Institute of Medical Research	Enhancing the Impact of FOLFIRINOX: Copper Chelation to Overcome Tumour Scarring and Improve Outcomes in Pancreatic Cancer
Dr Dannel Yeo	Garvan Institute of Medical Research	Transforming Pancreatic Cancer Care: Integrated Biomarkers for Effective Tailored Patient Management
Dr Ann-Na Cho	The University of Sydney	Bespoke Brain Tissue-on-a-Chip (BToC) Platform to Accelerate Precision Therapeutics for Amyotrophic lateral sclerosis
Dr Madeleine Strach	Centenary Institute of Cancer Medicine & Cell Biology	An avatar platform for personalised drug treatment of rare cancers
Dr Tuba Gide	Melanoma Institute Australia	Decoding Immune Predictors of Response to Experimental Immunotherapies in Clinical Trials: Neoantigens, HLA Genotypes, and Checkpoint Ligand-Receptor Axes
Dr Zhian Chen	The University of Queensland	Developing next-generation bi-specific immunotherapies by combining a novel cytokine agonism with immune checkpoint inhibitors
Dr Fiona Angrisano	The Macfarlane Burnet Institute for Medical Research and Public Health Ltd	Developing Vaccines to Block the Spread of Plasmodium vivax Malaria
Dr Mohammad Mirkhalaf	Queensland University of Technology	Translating Tough Bioceramic Constructs for Load-Bearing Bone Repair
Dr Sidonia Eckle	The University of Melbourne	Characterising and targeting a novel immune axis to treat Parietaria judaica pollen allergy

Perpetual's Philanthropic Services and advice are provided by Perpetual Trustee Company Limited (PTCo), ABN 42 000 001 007, AFSL 236643. This publication has been prepared by PTCo and it may contain information contributed by third parties. It contains general information only and is not intended to provide advice or take into account personal objectives, financial situation or needs. The information is believed to be accurate at the time of compilation and is provided by PTCo in good faith. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. PTCo does not warrant the accuracy or completeness of any information included in this document which was contributed by a third party.
